Abstracts

Filters

Clear Filters
All Days Sun, Sep 28 Mon, Sep 29 Tue, Sep 30 Wed, Oct 01

Sunday, September 28

1:00 PM - 1:10 PM PT

3 - 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer; Primary Endpoint Analysis of the Phase II LUNAR Randomized Trial
Speaker: Kishan, Amar, MD, PhD - UCLA, Culver City, California
1:00 PM - 2:30 PM PT

Clinical Trials
Speaker: Rosenzweig, Kenneth, MD, FASTRO - Icahn School of Medicine at Mount Sinai, New York, New York
1:00 PM - 2:30 PM PT

Clinical Trials
Speaker: Siddiqui, Farzan, MD, PhD, FASTRO - Henry Ford Hospital/Wayne State University, Detroit, MI
1:10 PM - 1:20 PM PT

4 - Decreasing the Dose of Consolidation Radiation Therapy in DLBCL/HGBL: A Phase II Trial by the International Lymphoma Radiation Oncology Group
Speaker: Kelsey, Christopher, MD, FASTRO - Duke University Medical Center, Durham, North Carolina
2:30 PM - 2:40 PM PT

100 - Multicenter, Phase 3 Randomized Trial of Stereotactic Radiation vs. Hippocampal Avoidance Whole Brain Radiation in Patients with 5-20 Brain Metastases: Recurrence, Salvage Therapy, and Mortality Endpoints
Speaker: Aizer, Ayal, MD - Brigham and Women's Hospital, Boston, MA
2:30 PM - 2:40 PM PT

107 - Quality of Life and 5-Year Long-Term Organ Preservation in Early Rectal Adenocarcinoma Final Results from the OPERA Trial
Speaker: ben Dhia, Syrine, MD - Antoine lacassagne center, nice
2:30 PM - 2:40 PM PT

114 - Phase 3, Randomized, Placebo Controlled Clinical Trial of CAN-2409+Prodrug in Combination with Standard of Care External Beam Radiation (EBRT) for Newly Diagnosed Localized Prostate Cancer
Speaker: Gejerman, Glen, MD, MBA - Hackensack University Medical Center, Hackensack, NJ
2:30 PM - 2:37 PM PT

121 - Impact of MMR Status vs. Clinicopathologic Risk Factors on Locoregional Recurrence in Stage I Endometrioid Endometrial Cancer Treated with Brachytherapy Alone
Speaker: Hathout, Lara, MD, FRCPC - Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
2:30 PM - 2:40 PM PT

127 - Mid-Treatment ctDNA to Predict Outcomes in Stage IIB-IIIC NSCLC Treated with MRI-Adapted Chemoradiation
Speaker: Hashmi, Ayesha, MD - Mayo Clinic Alix School of Medicine, Rochester, MN
2:30 PM - 2:40 PM PT

134 - Interrogating Contributions of the Sensory Neuroimmune Axis to Treatment Resistance in Head and Neck Squamous Cell Carcinoma
Speaker: Idlett-Ali, Shaquia, MD, PhD, BS - University of Colorado School of Medicine, Aurora, CO
2:30 PM - 3:45 PM PT

CNS 1: Novel Approaches in Brain Metastases
Speaker: Li, Puyao, MD - University of Vermont Medical Center, Burlington, VT
2:30 PM - 3:45 PM PT

CNS 1: Novel Approaches in Brain Metastases
Speaker: Yu, Hsiang-Hsuan, MD, MS, FASTRO - Moffitt Cancer Center, Tampa, FL